DrugCombination product
Survodutide clinical trials
Also written BI 456906.
- studies test it
- 35
- open now
- 8
- in phase 3
- 12
- first study started
- 2017
Keep track of what changes. Save the survodutide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
35 studies that test it; most in 2024 (11)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 5 |
| 2024 | 11 |
| 2025 | 4 |
| 2026 | 7 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 19
- Phase 2
- 4
- Phase 3
- 12
What it is tested for
Each study’s main condition, where its own words name it.
- Obesity
- 20
Who runs them
Industry 34 · Other 1
Boehringer Ingelheim (34) · University Medical Center Groningen (1)
Often tested with
Tested in the same studies.
Semaglutide (2) · BI 1820237 (2) · Bupropion (1) · Caffeine (1) · Midazolam (1)
Studies
Open first, then newest update. How each study uses survodutide is read from its arms, and is right about nine times in ten.
Testing it · 35
- ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver DiseaseNot yet recruitingPhase 3Boehringer IngelheimNCT07850063Written as Survodutide
- SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose WeightNot yet recruitingPhase 3Boehringer IngelheimNCT07850050Written as Survodutide
- LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver FibrosisRecruitingPhase 3Boehringer IngelheimNCT06632444Written as Survodutide
- LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have CirrhosisRecruitingPhase 3Boehringer IngelheimNCT06632457Written as Survodutide
- A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood SugarRecruitingPhase 3Boehringer IngelheimNCT07754461Written as Survodutide
- SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose WeightNot yet recruitingPhase 3Boehringer IngelheimNCT07855900Written as Survodutide
- A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or ObesityRecruitingPhase 1Boehringer IngelheimNCT07768813Written as Survodutide formulation A
- Albuminuria Reduction Study With Survodutide Treatment in Kidney DiseaseNot yet recruitingPhase 2University Medical Center GroningenNCT07206290Written as Survodutide (BI 456906)
- A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)CompletedPhase 3Boehringer IngelheimNCT06077864Written as survodutide
- A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the LiverActive, not recruitingPhase 1Boehringer IngelheimNCT05202353Written as BI 456906
- A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose WeightCompletedPhase 3Boehringer IngelheimNCT06066528Written as Survodutide
- A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up by the BodyCompletedPhase 1Boehringer IngelheimNCT07221591Written as survodutide
- A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like InjectorCompletedPhase 1Boehringer IngelheimNCT07413913Written as Survodutide formulation A
- A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With ObesityActive, not recruitingPhase 1Boehringer IngelheimNCT06745284Written as Survodutide
- A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)CompletedPhase 3Boehringer IngelheimNCT06309992Written as Survodutide
- A Study to Test Whether Survodutide Helps Japanese People Living With Obesity DiseaseCompletedPhase 3Boehringer IngelheimNCT06176365Written as Survodutide
- A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose WeightCompletedPhase 3Boehringer IngelheimNCT06214741Written as survodutide
- A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or ObesityCompletedPhase 1Boehringer IngelheimNCT06200467Written as BI 456906
- A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or ObesityCompletedPhase 1Boehringer IngelheimNCT06564441Written as Survodutide
- A Study in Healthy People to Compare How 3 Different Formulations of Survodutide Are Taken up in the BodyCompletedPhase 1Boehringer IngelheimNCT06772532Written as BI 456906 - Formulation A
Codes
What other systems call survodutide · ClinicalTrials.gg INT002004
- MeSH (NLM) C000726451survodutideConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 2ALA66NS64SURVODUTIDEConfirmed FDA, NLM
- NCI Thesaurus C199114SurvodutideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000726451 | survodutide | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 2ALA66NS64 | SURVODUTIDE | Confirmed FDA, NLM |
| NCI Thesaurus | C199114 | Survodutide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.